Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Aesica Expands Facility & Capabilities

By Aesica Pharmaceuticals | April 5, 2016

Aesica Pharmaceuticals announces the doubling of its development capacity—manufacturing multiple drug products up to phase 3 clinical trials at Queenborough.  

With the addition of the new capabilities, Aesica can now develop and manufacture a customer product from early formulation development through clinical manufacture and into commercialization—covering all aspects of product life cycle on the one site. This process will now be a seamless end-to-end service offering for the customer

The company’s high potent and controlled drugs service offering has been significantly expanded at Queenborough as a result of the new center. Whilst previously the company only provided commercials scale manufacturing capabilities for these drug classifications, it now offers full formulation and development capabilities in these specialist fields. The site handles high potent drugs for any active up to SafeBridge Category 3, together with controlled drugs, with licenses for both Schedules 2 to 4. Moreover, the facility is therefore experienced in handling drugs that are both highly potent and at the same time controlled.

Ian Muir, Managing Director of Aesica Pharmaceuticals commented: “In response to growing customer demand and as part of our on-going strategy to meet the needs of the market to simplify the supply chain with reliable, highly-efficient, single-source solutions, we have taken the strategic initiative to ensure that our high capacity Queenborough Development Center, which doubles our development capacity, combined with our commercial manufacturing capabilities at the facility, provides a complete service offering for formulation, development and product manufacturing for multiple customers.

“High potency is a key contract services market, with strong growth potential, requiring a mix of highly specialized and advanced technological skills and capabilities. We have set these resources in place and have now taken the strategic initiative to combine them with full clinical and commercial scale manufacturing capacity in this highly complex field from a single site location—further enhancing our offering to customers.”

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!

Related Articles Read More >

Sandoz Logo 2025
Sandoz breaks ground on biosimilar plant in Slovenia
Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Antheia_Logo (1)
Pharma ingredient manufacturer Antheia raises $56M Series C
Prolific Machines logo.
Prolific Machines enters FDA program to enhance therapeutics manufacturing platform
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE